---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-025587"
form_type: "8-K"
ticker: "TEM"
cik: "0001717115"
company_name: "Tempus AI, Inc."
filed_at: "2025-02-24T23:59:59+00:00"
generated_at: "2026-05-26T06:02:37.850033+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tempus AI Q4 revenue $200.7M (+35.8% YoY); guides FY25 revenue ~$1.24B, Adj. EBITDA ~$5M

## Summary
- Q4 revenue $200.7M (+35.8% YoY); Genomics $120.4M, Data $80.2M. Gross profit $122.1M (+49.7%).
- FY24 revenue $693.4M (+30.4%); net loss $705.8M (incl. $547.7M stock comp); Adj. EBITDA loss $104.7M.
- Closed Ambry Genetics acquisition Feb 3, 2025; combined FY25 revenue guidance ~$1.24B (+79% YoY).
- Expects FY25 Adj. EBITDA ~$5M (improvement of ~$110M over FY24).
- CMS reimbursement for Tempus ECG-AF algorithm at $138/test; xT CDx granted ADLT status with $4,500 reimbursement.

## SEC filing metadata
- accession: 0000950170-25-025587
- form_type: 8-K
- ticker: TEM
- cik: 0001717115
- company_name: Tempus AI, Inc.
- filed_at: 2025-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1717115/000095017025025587/0000950170-25-025587-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1717115/000095017025025587/tem-20250224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-025587
- JSON: https://secwatch.observer/filing/0000950170-25-025587.json
- Plain text: https://secwatch.observer/filing/0000950170-25-025587.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.